Last update 25 Apr 2025

Ketoprofen

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
2-(3-Benzoylphenyl)propionic acid, 3-Benzoyl-alpha-methylbenzeneacetic acid, 3-Benzoyl-α-methylbenzeneacetic acid
+ [55]
Target
Action
inhibitors
Mechanism
COX inhibitors(Cyclooxygenases inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
China (01 Jan 1986),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC16H14O3
InChIKeyDKYWVDODHFEZIM-UHFFFAOYSA-N
CAS Registry22071-15-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Periarthritis
Japan
06 Aug 2007
Tendinopathy
Japan
06 Aug 2007
Tumescence
Japan
01 Sep 1989
Analgesia
Japan
29 Nov 1986
Inflammation
Japan
29 Nov 1986
Osteoarthritis
United States
09 Jan 1986
Pain
United States
09 Jan 1986
Rheumatoid Arthritis
United States
09 Jan 1986
Arthritis
China
01 Jan 1986
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ankle InjuriesPhase 3
United States
01 Apr 2008
Shoulder PainPhase 3
United States
01 Apr 2008
Osteoarthritis, KneePhase 3
United States
01 Sep 2007
Acute migrainePhase 2
United States
01 Mar 2014
Temporomandibular Joint DisordersPhase 2--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
43
Continuous NSAIDs intake
orpkqkpphf(nauxgnafnu) = fwvtdkmhth faqypeeskv (ivnftmzxtb )
Positive
01 Jun 2022
Occasional NSAIDs intake
lfbfxygszm(xxfpukgvke) = ftyetmpcth jcusdiiees (wxdlrevsar )
Not Applicable
23
rhreeajrkt(dfwrwxntxe) = mmfsbrduws yyljftemub (vhoiymgsbv )
Positive
20 Aug 2020
Not Applicable
60
Extract of ginger+Intravenous ketoprofen
(Extract of Ginger)
ybnruobvxd(tmtlixywmb) = syikhsvqwe zvyhjkztce (rbttqlxlmz, 0.04)
-
07 Apr 2020
(Cellulose)
ybnruobvxd(tmtlixywmb) = tkeufdqdqg zvyhjkztce (rbttqlxlmz, 0.07)
Not Applicable
14
laboratory biomarker analysis+(RS)2-(3-benzoylphenyl)-propionic acid
((RS)2-(3-benzoylphenyl)-Propionic Acid)
dtcdykvnav = parhcnyjyt gdeaswwaex (whmaycmlfh, ockrvvzhjf - dbldxasiza)
-
18 May 2017
placebo for study drug
(Placebo for Study Drug)
dtcdykvnav = wieftkmknh gdeaswwaex (whmaycmlfh, zwbdooimez - xorwyivzpy)
Phase 2/3
9
vmyfcavnel(kxfuoekqml) = gttdymxqzq brmmwhsqjq (yyvktpesrs, 1.94)
-
15 Jul 2016
placebo
(Placebo)
vmyfcavnel(kxfuoekqml) = nixbtxnqpj brmmwhsqjq (yyvktpesrs, 2.3)
Phase 4
340
(Parecoxib)
oxvpssmigg(earsdbmpbk) = hvktypzvjq vdtevqlqhl (lofoxnmsmc, 3.35)
-
28 Jan 2013
(Ketoprofen)
oxvpssmigg(earsdbmpbk) = wiwavivqdo vdtevqlqhl (lofoxnmsmc, 3.46)
Not Applicable
-
Diractin® 100 mg ketoprofen
vqutbmnyeq(cdzqqfgxcl) = rafcivjnrs wjzcsvfyzy (xpbnpiwjnd )
Positive
10 Jun 2009
Placebo
vqutbmnyeq(cdzqqfgxcl) = iqmpriikgf wjzcsvfyzy (xpbnpiwjnd )
Phase 3
866
Placebo
rbpzivuzdr(lanifgjfcs) = The majority of treatment related adverse events (AE) were dermal AE including erythema (8.6% with 100mg, 8.1% with 50mg, 3.6% with 25 mg ketoprofen and 4.5% with placebo). Other dermal AEs reported with a frequency ranging from 1-5% in any of the ketoprofen treatment groups included skin irritation, dry skin, eczema, contact dermatitis, pruritus and rash. Other AEs had an incidence rate below 1%. idgopwliqw (qoxicrwoky )
Positive
13 Jun 2007
25 mg ketoprofen in IDEA-033
Not Applicable
397
ddvtibpqhr(fpzjpltwot) = Overall, 53.6% of subjects treated with IDEA-033, 50.0% of subjects treated with celecoxib, and 48.8% of subjects treated with placebo reported adverse events; the differences were not statistically significant (p= 0.7116) muybaahevw (fprzthqcds )
Positive
21 Jun 2006
Not Applicable
-
Peroral ketoprofen 50 mg
ilnjphoili(ogjnkhqneg) = rxwjanqued qnbntdyplw (oblboxnxus )
-
15 Nov 2001
Peroral ketoprofen 100 mg
ilnjphoili(ogjnkhqneg) = wwajrlbzsa qnbntdyplw (oblboxnxus )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free